To contact or not: an investigation into the polymeric surface interactions with human insulin and their therapeutic

Megren H A Fagihi1,2,3, Chanaka Premathilaka4, Laura Zopf2,5

  • 1School of Medicine, University College Dublin Belfield, Dublin 4 Ireland.

RSC Advances
|February 16, 2026
PubMed

Insulin, a therapeutic peptide used to treat Type I diabetes, interacts with polymers commonly found in healthcare settings via various hydrophobic interactions, which can trigger insulin agglomeration, thereby reducing its bioavailability and therapeutic efficacy. In this study, a fluorescein isothiocyanate (FITC)-labeled human insulin (λ ex = 490 nm; λ em = 498-530 nm) suspension (0.125 mg mL-1, 0.25 mg mL-1, and 0.5 mg mL-1) prepared at pH 3 was interacted with fluorescent amine- (λ ex = 560 nm; λ em = 570-650 nm) and acid-terminated (λ ex = 625 nm; λ em = 640-720 nm) polystyrene particles (1 µm) at 37 °C for t = 2 h, 4 h, 24 h, 48 h, and 72 h. The variable fluorescence lifetime of FITC, driven by pH fluctuations, was used as a molecular pH meter to map pH alterations within insulin agglomerates. Larger agglomerates, with higher lifetime variations, were noticed for the amine-terminated particles, especially at longer timepoints, whereas such fluctuations were relatively subtle in the acid-terminated ones. Regions with lifetime variation spread beyond the adsorbed insulin layer on particles and merged with the peripheral zones of lower lifetimes inside the agglomerates. The results suggest that polymeric surfaces alter insulin's biochemical properties, with probable implications of reduced bioactivity, poor glycemic control, and (potential) additional side effects.

Related Concept Videos

Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.5K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
17
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.5K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
805
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
857